The Active Pharmaceutical Ingredient Innovation Center (APIIC), a consortium of biotechnology industry, policy and academic leaders, said in a whitepaper released to the media on Jan. 24, that reshoring the manufacture of essential, life-saving pharmaceuticals was urgently needed.
This week’s Senate Banking Committee hearing on fentanyl was high on celebrity, short on solutions.
In Senate hearing: imported generic drugs facing consistent drug shortages need a government incentive program to help labs make life-saving commodity drugs domestically.
A recent study suggests that Americans prefer locally produced medications if they are unclear where the product was made or if the lab has received bad reviews from an FDA inspection.
Another Indian lab recalling eye drops following recalls in October and instances of blindness caused by other imports from India in March.
In the wake of the COVID pandemic, consumers have become painfully aware of America’s heavy dependence on imports. The recent Amoxicillin shortage in hospitals has
WASHINGTON — The Coalition for a Prosperous America (CPA) today applauded the introduction of the Producing Incentives for Long-term Production of Lifesaving Supply of Medicines
Trump’s call to reshore pharmaceutical production, especially critical medicine in short supply, will set the table for other presidential candidates. Reshoring America’s medicine supply chain is increasingly mainstream, and an easy sell to voters.
A Chinese cancer drug maker that has not been inspected by the FDA since 2018 is selling chemotherapy drugs to the U.S. due to shortages. When will the U.S. meet its critical medication needs?
The balance between scarcity and supply favors supply, even if that means importing drugs from labs the FDA has not inspected.
